Chinese Academy of Sciences

Fudan University

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Shanghai Miracogen Inc

Shanghai Haihe Pharmaceutical Co., Ltd.

Mabwell (Shanghai) Bioscience Co., Ltd.

Jiangsu Mabwell Health Pharmaceutical R&d Co., Ltd.

Mabwell Bioscience Co., Ltd.

Lanping Ma

Jingkang Shen

Tao Meng

Xin Wang

Ke Yu

Wei Zhang

Ting Yu

Yongliang Zhang

Qingrou Li

Xuesai Zhang

Qing Lin

Zhiyan Du

Jian Ding

Ying Chu Wang

Meiyu Geng

Jing Ai

Xia Peng

Hongli Peng

Ying Wang

Yinchun Ji

Bing Xiong

Rui Jin

Danqi Chen

Jinpeng Pei

Arie Zask

Yiyi Chen

Lanfang Meng

Yuelei Chen

Yuchi Ma

Jing Al

Lin Chen

A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.

Tissue factor-targeted antibody-drug conjugate

Disclosed are a new AXL-targeting monoclonal antibody and antibody-drug conjugate. Also disclosed is a method for preparing said antibody and antibody-drug conjugate. The AXL antibody of the present invention can bind with purified human AXL protein and multiple AXL on tumor cell surface with high effectiveness and high specificity. Said humanized antibody also has high affinity and low immunogenicity. Said AXL antibody-drug conjugate has markable performance against tumors having high AXL expression.

AXL-targeting antibody, antibody-drug conjugate, preparation method therefor, and use thereof

Provided in the present invention are a di-substituted maleic amide linker conjugated to an antibody and a preparation method and use thereof. In particular, the present invention conjugates a strongly cytotoxic active substance to a biomacromolecule through a class of new linkers. The class of linkers can selectively act simultaneously with disulphide chains, so as to greatly improve the substance homogeneity of a conjugate. The conjugate prepared by the linker of the present invention has a high inhibitory activity on a cell strain expressing the corresponding antigen. Also provided is a method for preparing the above-mentioned conjugate and the use.

Di-substituted maleic amide linker for antibody drug conjugating and preparation method and use thereof

Provided is a process of synthesizing a substituted pyridine and pyrimidine compound. Particularly, provided is a method for preparing a compound of formula III via a compound of formula II', wherein the definition of each of groups is as described as the description. Compound with other methods, the method in the present invention has features of high yield and a result product being easier to separate. 

Process of synthesizing substituted pyridine and pyrimidine compound

This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumors associated with abnormal protein tyrosine kinase. 

Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof

The present invention belongs to the field of pharmaceutical Chemistry. In particular, the present invention relates to a pyridopyrimidine or pyrimidopyrimidine compound as represented by general formula (I), or an isomer thereof or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, a preparation method, a pharmaceutical composition and uses thereof in preparing a mTOR inhibitor. As a mTOR inhibitor, the compound or the pharmaceutical composition thereof can be used for treating a disease or condition due to PI3K-AKT-mTOR signalling pathway malfunction. 

Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof

Growing community of inventors

Shanghai, China

Lanping Ma